A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Natalie YL Ngoi, Valerie Heong, Samuel Ow, Wen Yee Chay, Hee Seung Kim, Chel Hun Choi, Geraldine Goss, Jeffrey C Goh, Bee Choo Tai, Diana GZ Lim, Nivashini Kaliaperumal, Veonice B Au, John E Connolly, Jae-Weon Kim, Michael Friedlander, Kidong Kim, David SP Tan

ABSTRACT

Background The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma.

Primary objective To evaluate the efficacy of durvalumab (MEDI-4736) compared with standard chemotherapy in patients with recurrent ovarian clear cell carcinoma.

Study hypothesis Patients with recurrent ovarian clear cell carcinoma treated with durvalumab will have improved progression-free survival compared with those treated with chemotherapy of physician’s choice.

Trial design The MOCCA study is a multicenter, open-label, randomized phase II trial in patients with recurrent ovarian clear cell carcinoma, which recruited from eight sites across Gynecologic Cancer Group Singapore (GCGS), Korean Gynecologic-Oncology Group (KGOG), and Australia New Zealand Gynecological Oncology Group (ANZGOG). Enrolled patients were randomized in a 2:1 ratio to receive durvalumab or physician’s choice of chemotherapy until disease progression, intolerable toxicity, or withdrawal of patient consent.

Major inclusion/exclusion criteria Eligible patients required histologically documented diagnosis of recurrent ovarian clear cell carcinoma, as evidenced by WT1 negativity. All patients must have been of Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. have had previous treatment with, and progressed or recurred after prior platinum-based chemotherapy. No more than four prior lines of treatment were allowed and prior immune checkpoint inhibitor treatment was not permitted.

Primary endpoints The primary endpoint was the median progression-free survival following treatment with durvalumab, compared with physician’s choice of chemotherapy. Progression-free survival was defined as the time from the first day of treatment to the first observation of disease progression, or death due to any cause, or last follow-up.

Sample size The target sample size was 46 patients.

Estimated dates for completing accrual and presenting results Accrual has been completed and results are expected to be presented by mid-2021.

Trial registration Clinicaltrials.gov: NCT03405454.

INTRODUCTION

Ovarian clear cell carcinoma is distinct from other epithelial ovarian cancers in terms of epidemiology, clinicopathological features, gene expression profile, and immune microenvironment. In the Western world, this is an uncommon disease and accounts for only 6% of epithelial ovarian cancer in the United States, but is far more prevalent in Singapore, the Republic of Korea, Taiwan, and Japan, where clear cell cancers constitute up to 25% of diagnosed ovarian cancer. Histologically, ovarian clear cell carcinoma is characterized by cells containing abundant clear glycogen-containing cytoplasm and may be associated with surrounding features of endometriosis. Immunohistochemistry typically demonstrates negativity for Wilm’s tumor 1 (WT1) and p53, but is often positive for hepatocyte nuclear factor 1-beta (HNF1-β).

The treatment of women with advanced and recurrent ovarian clear cell carcinoma remains an area of significant unmet need. Clear cell ovarian cancers tend to occur in younger women and are associated with thromboembolic complications and paraneoplastic hypercalcemia. Furthermore, advanced ovarian clear cell carcinoma is a chemotherapy-resistant disease, with lower objective response rates to first-line platinum-based chemotherapy compared with high-grade serous ovarian cancers (11% vs 73%), and worse 5-year stage-adjusted disease specific survival. On disease relapse, objective response rates to second-line chemotherapy have been reported to be strikingly low, ranging between 6%–9%. Efforts to improve response rates to chemotherapy in ovarian clear cell carcinoma over the past decade have been unsuccessful, underscoring the need for further drug discovery to treat this resistant disease.
There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in clear cell ovarian cancer. Interestingly, clear cell ovarian cancer shares more similarity in gene expression profiles with clear cell renal cell carcinoma rather than to other subtypes of epithelial ovarian cancer, and is characterized by frequent somatic mutations in ARID1A, overexpression of MDM2, and upregulation of the phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt)- mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) signaling axes. The high level of somatic mutations and up to 15% of mismatch repair deficiency (dMMR) found in ovarian clear cell carcinoma provides a further rationale supporting the likelihood of response to immune checkpoint inhibitors. Increased expression of lymphocyte activation gene 3 (LAG3), T-cell immunoglobulin mucin-3 (TIM-3), and PD-1 in ovarian clear cell carcinoma has been linked to increased immune suppression, while PI3KCA mutations and ARID1A loss of function, together with upregulation of HNF1-β and activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways, lead to increased interleukin-6 (IL6) and -8 expression, and further immune suppression. ARID1A is integral in the SWI/Sucrose Non-Fermentable (SWI-SNF) chromatin remodeling complex and is seen in about 40% of clear cell cancers. The loss of ARID1A expression has been shown to correlate with chemo-resistance in this disease. Though the prognostic and predictive effects of ARID1A loss in ovarian clear cell carcinoma remain poorly defined, ARID1A-deficiency has been associated with compromised MMR, increased mutational load, and PD-L1 expression. In orthotopic and intraperitoneal mouse models of ARID1A-mutant ovarian cancer, compared with control tumors, increased and durable responses to anti-PD-L1 therapy was noted, leading to improved survival, providing rationale for the inhibition of PD-1/PD-L1 in this context.

Furthermore, early phase clinical trials of anti-PD-1/PD-L1 immune checkpoint inhibitors in epithelial ovarian cancer suggest a possible signal of efficacy for this approach in the clear cell histotype. In a phase II study of nivolumab in patients with platinum-resistant recurrent ovarian cancer, a response rate of 23% and disease control rate of 54% was noted, with three patients showing durable partial response. Notably, one of these three long-term responders was a patient with ovarian clear cell carcinoma. Supporting this finding, in the KEYNOTE-100 study, the response rate in patients with clear cell histology to pembrolizumab was 15.8%, compared with only 8% in the overall recurrent ovarian cancer population. Therefore, the use of immune checkpoint inhibitors inhibiting the PD-1/PD-L1 axis is intriguing for further investigation in ovarian clear cell carcinoma and forms the basis for the current trial. This represents the first randomized trial to evaluate the efficacy of the anti-PD-L1 immune checkpoint inhibitor, durvalumab, compared with chemotherapy, in patients with recurrent ovarian clear cell carcinoma.

**METHODS**

**Trial design**

The “Multicenter Phase II Randomized Trial of Durvalumab (MEDI-4736) vs Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA)” trial is an open-label study which recruited from eight sites across the Gynecologic Cancer Group Singapore (GCCS), Korean Gynecologic-Oncology Group (KOGO) and Australia New Zealand Gynecological Oncology Group (ANZGOG) groups, with institutional review board approval obtained from each site. Enrolled patients were randomized in a 2:1 ratio to receive durvalumab or physician’s choice of chemotherapy until disease progression, intolerable toxicity, or withdrawal of patient consent, for up to 24 months (Figure 1). Patients randomized to physician’s choice of chemotherapy were allowed to receive any systemic cytotoxic chemotherapy, however the addition of biologics including bevacizumab, or oral tyrosine kinase inhibitors, was prohibited. On discontinuation of chemotherapy due to disease progression or intolerable toxicity, patients randomized to physician’s choice of chemotherapy were allowed crossover to receive durvalumab after completing a wash-out period of 4 weeks from the last anti-cancer therapy. Patients who discontinued treatment due to disease progression were followed up for a duration of 90 days from the end of study drug administration. Patients who discontinued treatment due to unacceptable adverse events were followed up monthly until the adverse event resolved, became stabilized or was no longer related. During the study, a cycle was 4 weeks for both arms. Allowances were made for dose reductions due to treatment-related toxicities. Efficacy assessment using tumor measurements and serum CA-125 was performed every 8 weeks. Tumor response was determined using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for patients on both arms, and modified RECIST was also evaluated for patients randomized to durvalumab.
Participants
Eligible patients required histologically documented diagnosis of recurrent ovarian clear cell carcinoma, as evidenced by WT1 negativity. If tumors were of mixed histology, >70% of the tumor must consist of clear cell carcinoma. All patients must provide informed consent to participate in the study, have been of Eastern Cooperative Oncology Group (ECOG) performance status 2 or better, and have had previous treatment with, and progressed or recurred after prior platinum-based chemotherapy. No more than four prior lines of systemic treatment were allowed. Prior immune checkpoint inhibitor treatment was not permitted. Patients must have had one or more measurable lesions by RECIST 1.1 criteria within 28 days of treatment commencement. Patients with active or prior documented autoimmune disease within the previous 2 years, or who received recent systemic immunosuppressive treatments, were excluded. Finally, all patients were required to provide archival tissue of sufficient quantity for translational analysis.

Primary endpoint
The primary endpoint of the MOCCA trial is progression-free survival following treatment with durvalumab or physician's choice chemotherapy. Progression-free survival was defined as the time from the first day of treatment to the first observation of disease progression, or death due to any cause, or censored at the date of last follow-up. Radiological disease progression was evaluated by RECIST 1.1 criteria for patients on the chemotheraphy arm, and by RECIST 1.1 and modified RECIST for patients on the durvalumab arm.

Secondary endpoints
The secondary endpoints of this study include the following – to determine the objective response rate of durvalumab or physician's choice chemotherapy in patients with recurrent ovarian clear cell carcinoma, to determine the overall survival of patients with recurrent ovarian clear cell carcinoma treated with durvalumab compared with physician's choice chemotherapy, and to determine the adverse event profile of durvalumab and to evaluate the effect of durvalumab or physician's choice chemotherapy on health-related quality of life, as measured using the European Organization for Research and Treatment of Cancer (EORTC) Core questionnaire QLQ-C30 and OV28.

Exploratory endpoint
The exploratory endpoint of this study is to identify predictive novel biomarkers of response and resistance to durvalumab in recurrent ovarian clear cell carcinoma. Potential biomarkers of response and resistance that will be studied include: PTEN loss, PIK3CA, ARID1A mutations, MMR status, PD-1/PD-L1 overexpression, cytokines, lymphocyte activation markers, human leukocyte antigen class I/II, and immune regulator status and expression.

Sample size
The sample size was estimated based on the primary endpoint of progression-free survival. A retrospective analysis of median progression-free survival in patients with ovarian clear cell carcinoma was 11 weeks.13 Hence, a HR of 0.50 was postulated assuming a median progression-free survival of 10 weeks in the chemotherapy arm and 20 or more weeks in the durvalumab arm. Based on a 6-month progression-free survival probability of 15% in the chemotherapy arm,13 a 2:1 treatment allocation, a one-sided 10% significance level, and a power of 80%, a sample size of 31 patients in the durvalumab arm and 15 patients in the chemotherapy arm was required, giving a total sample size of 46 patients.

Randomization and blinding
The Cenduit Interactive Web Response System was used to generate the dynamic block randomization allocation sequence (block size of six), with stratification by ECOG performance status.

Statistical methods
All enrolled patients receiving at least one dose of study medication will be included in the description of all demographic, baseline characteristic analysis as well as safety analysis. All patients completing one cycle of therapy were considered evaluable. Patients who discontinued treatment before completing one cycle for reasons other than progression were replaced.

The primary and secondary endpoints of progression-free survival and overall survival will be summarized using the Kaplan–Meier method with comparison of survival distributions made via the log-rank test. The secondary endpoint of objective response rate will be compared using Fisher's exact test, with the exact binomial 95% confidence intervals estimated for quantifying the difference in proportion. The secondary endpoint of health-related quality of life will be assessed by comparing the mean difference in domain scores using the Student's \( t \)-test. Statistical analyses for the primary and secondary outcomes will be conducted based on the principle of intention to treat, assuming a one-sided test at the 10% level of significance.

DISCUSSION
The immune-suppressive milieu in ovarian clear cell carcinoma arising from genetic alterations as well as tumor microenvironmental changes highlight the potential therapeutic role for immune checkpoint inhibitors in this chemotherapy-refractory disease. A recent study has suggested molecular heterogeneity within clear cell ovarian cancer, with two distinct and consistent immune-related gene expression subgroups denoted Epithelial-like (EpiCC) and Mesenchymal-like (MesCC), being defined.14 MesCC subtype clear cell cancers were associated with the expression of immune-related genes, higher enrichment of immune-related pathway activity, and tumor infiltrating lymphocytes compared with EpiCC subtype, but the impact of gene expression subtype on immunotherapy response remains unknown. Currently, several studies are evaluating the role of immune checkpoint inhibitors in ovarian clear cell carcinoma. The MOCCA trial has completed recruitment and represents the first study to evaluate the efficacy of anti-PD-L1 therapy compared with chemotherapy in advanced or recurrent clear cell ovarian cancer. Importantly, flow cytometry, RNA sequencing, and cytokine analysis performed on tumor and paired blood samples obtained during the trial, will aim to determine the immune profiles of patients which correlate with durvalumab response or resistance, and may help to shed light on potential biomarkers for patient selection. Other ongoing studies of immune checkpoint inhibitor therapy in this disease are the IND.228 study, which is a single-arm phase II study examining the efficacy of durvalumab + tremelimumab in advanced rare tumors, including

ovarian clear cell carcinoma (NCT02879162), as well as the BrUOG 354 study which is a randomized phase II study comparing nivolumab ± ipilimumab in persistent or recurrent ovarian clear cell carcinoma (NCT03355976). Their results are eagerly awaited and may be able to finally advance treatment paradigms for this fatal disease. Recent data showing efficacy for lenvatinib plus pembrolizu-zumab in patients with advanced recurrent clear cell endometrial cancer also suggests that the combination of vascular endothelial growth factor and PD-1 pathway inhibition should also be studied in ovarian clear cell carcinoma in the future. Crucially, it is hoped that translational studies from the aforementioned trials will also help to determine the relevant biomarkers of sensitivity and resistance to immune checkpoint inhibitors in ovarian clear cell carcinomas and help transform the treatment for patients affected by this challenging disease.

Author affiliations
1Department of Haematology-Oncology, National University Cancer Institute, Singapore
2Department of Medical Oncology, Tan Tock Seng Hospital, Singapore
3Division of Medical Oncology, National Cancer Centre Singapore, Singapore
4Department of Obstetrics and Gynecology, Seoul National University, Seoul, Republic of Korea
5Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Republic of Korea
6Box Hill Hospital, Box Hill, Victoria, Australia
7Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia
8The University of Queensland, Saint Lucia, Queensland, Australia
9Saw Swee Hock School of Public Health, National University of Singapore, Singapore
10Yong Loo Lin School of Medicine, National University of Singapore, Singapore
11Department of Pathology, National University Hospital, Singapore
12Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore
13Institute of Biomedical Studies, Baylor University, Waco, Texas, USA
14The Prince of Wales Hospital, Randwick, New South Wales, Australia
15Prince of Wales Clinical School University of New South Wales, Randwick, New South Wales, Australia
16Seoul National University Bundang Hospital, Seoul, Republic of Korea
17Cancer Science Institute Singapore, Singapore

Twitter Kidong Kim @KIDONG_KIM_MD

Acknowledgements This study was supported by a research grant from AstraZeneca.

Contributors Conceptualization: all authors data curation: NYLN writing—original draft preparation: NYLN writing—review and editing: all authors visualization: all authors supervision: DT project administration: Vilianty. Draft preparation: NYLN writing–review and editing: all authors visualization: all authors

Competing interests VH has received honoraria from AstraZeneca. SO has received honoraria from AstraZeneca. JCG has received honoraria and sponsorship funding from AstraZeneca. MF has received honoraria and research funding from Astra Zeneca.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

Data availability statement No data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs Natalie YL Ngoi http://orcid.org/0000-0003-2071-0715
Kidong Kim http://orcid.org/0000-0001-9254-6024

REFERENCES